Research Keyword: schizophrenia

Psychotomimetic compensation versus sensitization

mycolabadmin

This paper proposes a new way to understand why drugs that can cause psychosis-like effects (such as psilocybin, LSD, and ketamine) can also help treat depression and anxiety. The authors suggest that these drugs trigger compensatory responses in the brain that temporarily help us cope with stress, similar to how a runner’s high feels good during exercise. However, if someone uses these drugs repeatedly or experiences chronic stress, they may become sensitized and more vulnerable to developing actual psychotic symptoms over time.

Read More »

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia

mycolabadmin

Schizophrenia involves excessive loss of connections between brain cells in areas responsible for emotion and thinking, leading to negative symptoms and cognitive problems. Research shows that small doses of psychedelics like psilocybin can promote the growth of new brain connections and reduce inflammation. The authors suggest that microdosing psychedelics alongside standard treatments might help restore these lost connections and improve symptoms that don’t respond well to current medications.

Read More »

Reconsidering evidence for psychedelic-induced psychosis: An overview of reviews, a systematic review, and meta-analysis of human studies

mycolabadmin

This research review examined whether people with schizophrenia can safely participate in psychedelic-assisted therapy treatments. Researchers analyzed 131 studies and found that psychedelics rarely cause new psychosis in the general population (0.002%), though the risk is slightly higher in people with existing schizophrenia (3.8%). While the immediate risk appears manageable, about 13% of people who develop psychosis from psychedelics go on to develop schizophrenia, suggesting caution is still needed.

Read More »

Identification of a psychiatric risk gene NISCH at 3p21.1 GWAS locus mediating dendritic spine morphogenesis and cognitive function

mycolabadmin

Researchers identified a gene called NISCH that increases the risk of schizophrenia and bipolar disorder. When this gene is overactive, it changes the shape of connections between brain cells and impairs working memory in mice. Interestingly, blood pressure medications like clonidine can reduce NISCH activity and improve cognitive function, suggesting these drugs might help psychiatric patients.

Read More »

Syndrome of Subjective Doubles: Delusions of Identity and Duplication

mycolabadmin

A 23-year-old man believed that a musician he saw on social media was actually his identical duplicate, causing him significant distress and confusion about his own identity. His belief that he might be the ‘dead’ version persisted for years until he sought psychiatric help due to worsening symptoms. Treatment with the antipsychotic medication olanzapine, combined with therapy, successfully reduced his delusions and hallucinations within five days of hospitalization. This rare condition highlights how certain psychiatric disorders can cause profound disturbances in how people perceive their own identity.

Read More »
Scroll to Top